Laboratorios Farmaceuticos Rovi, SA
ROVI
ISIN ES0157261019 / Valor 3591807
Laboratorios Farmaceuticos Rovi, SA
UMushroom community rating:
About company
Laboratorios Farmacéuticos Rovi, S.A. is a Spanish pharmaceutical company that develops, manufactures and commercializes generic and specialty medicines, with a focus on injectable products, thrombosis treatments and contract manufacturing services.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (19.05.2026):
Laboratorios Farmaceuticos Rovi, SA — full-year 2025 results (from the company report): the company reports total operating revenues of €743.5m in 2025, driven by its Especialidades farmacéuticas division and CDMO activities, with notable increases in R&D spending and an international presence for its core low‑molecular‑weight heparin (HBPM).
Total operating revenue
Operating revenues of €743.5 million in 2025 (company-reported figure).
Especialidades farmacéuticas
Sales of the Specialties business: €473.9 million in 2025; portfolio described as diversified, with innovative own products and licensed, patent-protected medicines. HBPM (low‑molecular‑weight heparin) identified as the principal product.
CDMO activity
CDMO sales of €269.5 million in 2025. Company states high production capacity with three manufacturing plants for prefilled syringes and oral solid dosage forms.
R&D investment
R&D spend of €37.8 million in 2025, an increase of +47% versus 2024 (company-reported).
Geographic presence
HBPM is present in over 60 countries through strategic partnerships with international partners.
Corporate/investor note
Company emphasizes transparency for investors (“Espacio del inversor”) and provides detailed information on results and figures in its report.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
3426 M
Market cap (USD)
85,454
Daily traded volume (Shares)
62.2 / 61.3
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Sas Cas
EQUITIES OF THE SAME SECTOR
